ATE553108T1 - Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors - Google Patents

Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors

Info

Publication number: ATE553108T1
Authority: AT; Austria
Prior art keywords: thiazoloa4; cupyridine; antagonists; derivative; mglu5 receptor
Prior art date: 2005-11-08

Application number

AT06807563T

Other languages

English (en)

Inventor

Georg Jaeschke

Sabine Kolczewski

Richard H P Porter

Patrick Schnider

Eric Vieira

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-08

Filing date

2006-10-26

Publication date

2012-04-15

2006-10-26 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE553108T1 publication Critical patent/ATE553108T1/de

Links

101001032845 Homo sapiens Metabotropic glutamate receptor 5 Proteins 0.000 title 1
102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 title 1
239000005557 antagonist Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Psychology (AREA)
Addiction (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT06807563T 2005-11-08 2006-10-26 Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors ATE553108T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05110461		2005-11-08
PCT/EP2006/067794 WO2007054436A2 (en)	2005-11-08	2006-10-26	Thiazolo [4 , 5-c] pyridine derivatives as mglu5 receptor antagonists

Publications (1)

Publication Number	Publication Date
ATE553108T1 true ATE553108T1 (de)	2012-04-15

Family

ID=37897285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06807563T ATE553108T1 (de)	2005-11-08	2006-10-26	Thiazoloä4,5-cüpyridinderivative als antagonisten des mglu5-rezeptors

Country Status (16)

Country	Link
US (1)	US7659401B2 (de)
EP (1)	EP1948667B1 (de)
JP (1)	JP5015166B2 (de)
KR (1)	KR101020431B1 (de)
CN (1)	CN101291939B (de)
AR (1)	AR058179A1 (de)
AT (1)	ATE553108T1 (de)
AU (1)	AU2006311084A1 (de)
BR (1)	BRPI0618636A2 (de)
CA (1)	CA2628936A1 (de)
ES (1)	ES2382162T3 (de)
IL (1)	IL190989A0 (de)
RU (1)	RU2425834C2 (de)
TW (1)	TWI323261B (de)
WO (1)	WO2007054436A2 (de)
ZA (1)	ZA200803821B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100144756A1 (en)	2007-07-13	2010-06-10	Bolea Christelle	Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
GB0800411D0 (en) *	2008-01-10	2008-02-20	Glaxo Group Ltd	Novel compounds
AU2010332811B2 (en) *	2009-12-18	2014-07-24	Janssen Pharmaceutica Nv	Bicyclic thiazoles as allosteric modulators of mGluR5 receptors
WO2011073347A1 (en)	2009-12-18	2011-06-23	Janssen Pharmaceutica Nv	Bicyclic thiazoles as allosteric modulators of mglur5 receptors
US9895358B2 (en)	2016-02-23	2018-02-20	Indiana University Research And Technology Corporation	Combination therapies for treatment of spinal muscular atrophy
KR102224677B1 (ko)	2018-08-23	2021-03-08	가천대학교 산학협력단	티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3864248D1 (de)	1987-12-14	1991-09-19	Sawai Seiyaku Kk	Carboxamide mit tetrazol- und thiazol-ringen und ihre anwendung.
JP2695037B2 (ja) *	1990-11-07	1997-12-24	富士通株式会社	エラーパルス延伸回路
US6107300A (en) *	1996-03-27	2000-08-22	Dupont Pharmaceuticals	Arylamino fused pyrimidines
AU3571997A (en)	1996-08-01	1998-02-25	Warner-Lambert Company	Novel glutamate receptor antagonists: fused cycloalkyl quinoxalinediones
EP1025501B1 (de) *	1997-10-29	2002-04-03	Continental Teves AG & Co. oHG	Verfahren und vorrichtung zur überprüfung einer fehlerüberwachung einer schaltung
US6110929A (en) *	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
US6660753B2 (en)	1999-08-19	2003-12-09	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
CN1313465C (zh)	1999-08-19	2007-05-02	Nps药物有限公司	杂多环化合物及其用于制备代谢性谷氨酸受体拮抗剂的应用
KR100865096B1 (ko)	2000-11-30	2008-10-24	캐논 가부시끼가이샤	발광 소자 및 표시 장치
JP4155351B2 (ja) *	2001-02-20	2008-09-24	中外製薬株式会社	代謝調節剤として有用なマロニル−ＣｏＡ脱炭酸酵素阻害剤としてのアゾール
CA2438991C (en)	2001-02-21	2010-08-17	Nps Pharmaceuticals, Inc.	Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
WO2002078745A2 (en)	2001-04-02	2002-10-10	Brown University Research Foundation	Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
US6529046B1 (en) *	2001-12-12	2003-03-04	Etron Technology, Inc.	Minimum pulse width detection and regeneration circuit
AU2003270701B2 (en) *	2002-10-31	2009-11-12	Amgen Inc.	Antiinflammation agents
ITMI20030151A1 (it) *	2003-01-30	2004-07-31	Recordati Ind Chimica E Farma Ceutica S P A	Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
EP1781647A2 (de)	2004-07-22	2007-05-09	Astex Therapeutics Limited	Thiazol- und isothiazolderivate als proteinkinaseinhibitoren
WO2006106326A1 (en) *	2005-04-06	2006-10-12	Astrazeneca Ab	Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors

2006
- 2006-10-26 JP JP2008539390A patent/JP5015166B2/ja not_active Expired - Fee Related
- 2006-10-26 CA CA002628936A patent/CA2628936A1/en not_active Abandoned
- 2006-10-26 BR BRPI0618636-0A patent/BRPI0618636A2/pt not_active IP Right Cessation
- 2006-10-26 AU AU2006311084A patent/AU2006311084A1/en not_active Abandoned
- 2006-10-26 AT AT06807563T patent/ATE553108T1/de active
- 2006-10-26 EP EP06807563A patent/EP1948667B1/de not_active Not-in-force
- 2006-10-26 ES ES06807563T patent/ES2382162T3/es active Active
- 2006-10-26 RU RU2008115034/04A patent/RU2425834C2/ru not_active IP Right Cessation
- 2006-10-26 WO PCT/EP2006/067794 patent/WO2007054436A2/en not_active Ceased
- 2006-10-26 CN CN2006800386693A patent/CN101291939B/zh not_active Expired - Fee Related
- 2006-10-26 KR KR1020087013474A patent/KR101020431B1/ko not_active Expired - Fee Related
- 2006-10-31 US US11/590,087 patent/US7659401B2/en not_active Expired - Fee Related
- 2006-11-06 AR ARP060104855A patent/AR058179A1/es not_active Application Discontinuation
- 2006-11-06 TW TW095140997A patent/TWI323261B/zh not_active IP Right Cessation
2008
- 2008-04-17 IL IL190989A patent/IL190989A0/en unknown
- 2008-05-05 ZA ZA200803821A patent/ZA200803821B/xx unknown

Also Published As

Publication number	Publication date
IL190989A0 (en)	2008-12-29
ZA200803821B (en)	2009-03-25
KR20080069229A (ko)	2008-07-25
JP2009514923A (ja)	2009-04-09
WO2007054436A3 (en)	2007-06-28
BRPI0618636A2 (pt)	2011-09-06
CA2628936A1 (en)	2007-05-18
TWI323261B (en)	2010-04-11
US7659401B2 (en)	2010-02-09
AU2006311084A1 (en)	2007-05-18
EP1948667A2 (de)	2008-07-30
RU2008115034A (ru)	2009-12-20
RU2425834C2 (ru)	2011-08-10
KR101020431B1 (ko)	2011-03-08
ES2382162T3 (es)	2012-06-05
US20070105891A1 (en)	2007-05-10
EP1948667B1 (de)	2012-04-11
CN101291939A (zh)	2008-10-22
CN101291939B (zh)	2013-02-13
TW200736264A (en)	2007-10-01
JP5015166B2 (ja)	2012-08-29
WO2007054436A2 (en)	2007-05-18
AR058179A1 (es)	2008-01-23

Publication	Publication Date	Title
ATE505467T1 (de)	2011-04-15	2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
DE602006015607D1 (de)	2010-09-02	Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE509928T1 (de)	2011-06-15	8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
NL1032713A1 (nl)	2007-05-01	Histamine-3-receptorantagonisten.
DE602007009305D1 (de)	2010-10-28	Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
ATE496051T1 (de)	2011-02-15	Pyrazolotetrahydropyridinderivate als orexinrezeptorantagonisten
ATE441639T1 (de)	2009-09-15	2,4-diamino-pyrimidine als aurora inhibitoren
ATE461932T1 (de)	2010-04-15	Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
ATE490254T1 (de)	2010-12-15	Imidazoä1,2-aüpyridin-verbindungen als vegf-r2- hemmer
ZA200800320B (en)	2009-02-25	Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ATE508119T1 (de)	2011-05-15	Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE555111T1 (de)	2012-05-15	Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ATE537151T1 (de)	2011-12-15	Pyrazolinverbindungen als mineralocorticoidrezeptorantagonisten
NL1030961A1 (nl)	2006-07-21	Gesubstitueerde triazoolderivaten als oxytocineantagonisten.
ATE518834T1 (de)	2011-08-15	2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE477243T1 (de)	2010-08-15	2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
DK1973886T3 (da)	2013-03-18	Prokineticin-1-receptor-antagonister
DE602006019624D1 (de)	2011-02-24	Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors
ATE429428T1 (de)	2009-05-15	Indanderivate als antagonisten des mch-rezeptors
NL2000241A1 (nl)	2007-03-22	Carboxamidederivaten als muscarine-receptorantagonisten.
ATE538123T1 (de)	2012-01-15	2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
DE502006001027D1 (de)	2008-08-14	Cyanuraten
ATE469900T1 (de)	2010-06-15	Spiropiperidinderivate als antagonisten des via- rezeptors
ATE535523T1 (de)	2011-12-15	Benzimidazolcarbonsäureamid-verbindungen als 5- ht4 rezeptor-agonisten
DE602006003666D1 (de)	2008-12-24	Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten